Blue Jet Healthcare Ltd

Blue Jet Healthcare Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure will be effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Standalone Financial Results for the quarter and half-year ended September 30, 2026. This measure is in compliance with the company's internal code of conduct and SEBI (Prohibition of Insider Trading) Regulations, 2015, aimed at preventing insider trading.

Blue Jet Healthcare Ltd. has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, in compliance with SEBI regulations. The report, available on the company's website, details its corporate identity, operations, products, and employee data. The company's primary business activity is the manufacturing of chemicals, pharmaceuticals, and medicinal products, accounting for 100% of its turnover. Key products include Contrast Media (53%), High Intensity Sweeteners (14%), and Pharmaceutical Intermediaries/APIs (33%). The company operates 8 national locations and serves over 50 countries internationally, with exports contributing approximately 90% of its total turnover. The report is prepared on a standalone basis and has undergone reasonable assurance assessment by TUV India Pvt Ltd.

Blue Jet Healthcare Ltd has announced its 58th Annual General Meeting (AGM) will be held on September 21, 2026, at 11:00 AM IST via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The meeting will address ordinary business including the adoption of audited standalone financial statements for FY26, declaration of a dividend of ₹1.20 per share, and the re-appointment of Mr. Naresh Suryakant Shah. Special business includes the re-appointment of M/s. KKC & Associates LLP as Statutory Auditors for a second five-year term and the re-appointment of Mr. Akshay Bansarilal Arora as Whole-Time Director and Executive Chairman for five years from April 13, 2027.

Blue Jet Healthcare Ltd. has released its Annual Report for the financial year 2025-26, along with the notice for its 58th Annual General Meeting (AGM) scheduled for September 21, 2026. The report details the company's transition into a strategic CDMO partner, emphasizing its "Collaboration, Development, Manufacturing" approach. Key operational highlights include the agreement to purchase 102.48 acres of industrial land in Andhra Pradesh for a new manufacturing facility for ₹435.02 million and securing a lease for an additional R&D center in Hyderabad focused on emerging technologies like GLP-1 intermediates and peptide chemistry. The company is investing in R&D, manufacturing capacity, and advanced capabilities to meet evolving global healthcare needs.

Blue Jet Healthcare Limited's Board of Directors convened on August 3, 2026, approving the unaudited standalone financial results for the first quarter ended June 30, 2026. The board also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman for five years from April 13, 2027. Additionally, Mr. Shiven Akshay Arora was re-appointed as Managing Director for a similar term. M/s KKC & Associates LLP were re-appointed as Statutory Auditors for a second five-year term. The company also announced a record date of September 14, 2026, for a dividend of ₹1.2 per equity share for FY 2025-26 and scheduled its 58th AGM for September 21, 2026.

Blue Jet Healthcare Ltd's Board of Directors convened on August 3, 2026, approving the unaudited standalone financial results for the first quarter ended June 30, 2026. The board also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman for five years from April 13, 2027. Additionally, Mr. Shiven Akshay Arora was re-appointed as Managing Director for a similar term. M/s KKC & Associates LLP were re-appointed as Statutory Auditors for a second five-year term. The company also announced a record date of September 14, 2026, for a dividend of ₹1.2 per equity share for FY 2025-26, and scheduled its 58th AGM for September 21, 2026.

Blue Jet Healthcare Limited's Board of Directors convened on August 3, 2026, approving the unaudited standalone financial results for the first quarter ended June 30, 2026. The board also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman for five years from April 13, 2027. Additionally, Mr. Shiven Akshay Arora was re-appointed as Managing Director for a similar term. M/s KKC & Associates LLP were re-appointed as Statutory Auditors for a second five-year term. The company also announced a record date of September 14, 2026, for a dividend of ₹1.2 per equity share for FY 2025-26 and scheduled its 58th AGM for September 21, 2026.

Blue Jet Healthcare Ltd announced its unaudited standalone financial results for the first quarter ended June 30, 2026. The Board of Directors also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman, and Mr. Shiven Akshay Arora as Managing Director, both for a further period of five years effective April 13, 2027. M/s KKC & Associates LLP were re-appointed as Statutory Auditors for a second term of five years. The company also set a record date of September 14, 2026, for a dividend of ₹1.2 per equity share for FY25-26. The 58th Annual General Meeting is scheduled for September 21, 2026.

Blue Jet Healthcare opened FY27 with a year-on-year decline: standalone revenue from operations of ₹293.11 Cr fell 17.4% against a strong ₹354.76 Cr in Q1 FY26, and net profit of ₹78.26 Cr was down 14.2% from ₹91.17 Cr. The optics are far better sequentially — revenue up 24.9% and PAT up 21.6% over a soft Q4 FY26 — but the year-ago base is the primary read, and on that measure the quarter is a step down for a company management had positioned for a "commercialization and growth cycle" in FY27. Margins were the redeeming feature: net margin held at ~25.4% of total income (vs ~25.1% a year ago), and gross material cost eased to ~47% of sales (from ~52%), even as reported cost of materials jumped on a ₹41.77 Cr inventory build. Operating margin at ~33.5% slipped only marginally from 34.1% YoY, while other income of ₹15.24 Cr (up from ₹8.25 Cr) cushioned the bottom line. So this is a topline-and-volume problem, not a profitability one — the single reportable segment (sweeteners, contrast media intermediates, pharma intermediates/APIs) simply did less business than in a bumper year-ago quarter, with the PI/API normalisation management flagged not yet visible in the print. The result sits awkwardly against expectations. Street consensus embeds ~23% revenue and ~21% profit growth for full-year FY27 (Trendlyne, 5 analysts), and management's own last-call guidance was for double-digit contrast-media growth plus PI/API recovery beyond FY25 peaks — a 17% YoY revenue decline in Q1 is a soft start against both, implying heavy H2 back-loading is now required. On corporate actions the quarter was busy: the board declared a ₹1.2/share (60%) FY26 dividend (record date Sep 14), re-appointed Executive Chairman Akshay Arora and MD Shiven Arora for five-year terms (Apr 2027–2032) and reappointed auditor KKC, and — just after quarter-end — closed an ₹800 Cr QIP at ₹506/share (1.58 Cr new shares) earmarked for the Vizag greenfield and Mahad completion. That raise strengthens the balance sheet for the promised capex cycle but will dilute EPS (already ₹4.51 vs ₹5.26 YoY) until the new capacity contributes.

Blue Jet Healthcare Ltd has announced that its Board of Directors will convene on August 3, 2026. The primary agenda item is the consideration and approval of the Unaudited Standalone Financial Results for the first quarter ended June 30, 2026, along with the Limited Review Report. The company also confirmed that the trading window for designated persons will remain closed until 48 hours after the declaration of these financial results, reopening on August 6, 2026.